Although we demonstrated that CBX4 activates β-catenin signaling and its transcriptional activity, we did not identify or validate the specific downstream target genes (e.g., c-MYC, CCND1, AXIN2) responsible for mediating the oncogenic effects of CBX4 in gastric cancer. This evidence concerns the gene AXIN2 and gastric cancer.